Ramón
García Sanz
Profesor Titular de Universidad
Harvard Medical School
Boston, Estados UnidosPublicaciones en colaboración con investigadores/as de Harvard Medical School (22)
2023
-
Highlights of the 11th International Workshop on Waldenstrom's Macroglobulinemia: What we learned, and how it will impact scientific discovery and patient care
Seminars in Hematology
-
Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia
Seminars in Hematology
-
Report of Consensus Panel 6 from the 11 th International Workshop on Waldenström's Macroglobulinemia on Management of Waldenström's Macroglobulinemia Related Amyloidosis
Seminars in Hematology
-
Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients
Seminars in Hematology
-
Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients
Seminars in Hematology
-
Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management
Seminars in Hematology
-
Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials
Seminars in Hematology
2022
-
High frequency of central nervous system involvement in transformed Waldenstrom € macroglobulinemia
Blood Advances
-
IBCL-117 ASPEN: Long-Term Follow-Up Results of a Phase 3 Randomized Trial of Zanubrutinib vs Ibrutinib in Patients With Waldenström Macroglobulinemia
Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S385
2021
-
Denosumab compared with zoledronic acid on PFS in multiple myeloma: Exploratory results of an international phase 3 study
Blood Advances, Vol. 5, Núm. 3, pp. 725-736
-
Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group
The Lancet Oncology, Vol. 22, Núm. 3, pp. e119-e130
2020
-
A prognostic index predicting survival in transformed Waldenström macroglobulinemia
Haematologica, Vol. Online ahead of print
-
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: The ASPEN study
Blood, Vol. 136, Núm. 18, pp. 2038-2050
-
Genomic evolution of ibrutinib-resistant clones in Waldenström macroglobulinaemia
British Journal of Haematology, Vol. 189, Núm. 6, pp. 1165-1170
-
Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: A substudy of the phase 3 ASPEN trial
Blood Advances, Vol. 4, Núm. 23, pp. 6009-6018
2016
-
Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): A multi-institutional retrospective study
British Journal of Haematology, Vol. 172, Núm. 5, pp. 709-715
-
Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia
British Journal of Haematology, Vol. 175, Núm. 1, pp. 77-86
-
Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia
Blood, Vol. 128, Núm. 10, pp. 1321-1328
2014
-
C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma
Blood, Vol. 123, Núm. 26, pp. 4120-4131
-
Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus
Blood, Vol. 124, Núm. 9, pp. 1404-1411